{
    "organizations": [],
    "uuid": "9bfa76de8e021112b1de96bc156deaa9ea22d64f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-redhill-biopharma-announces-two-or/brief-redhill-biopharma-announces-two-oral-presentations-on-bekinda-24-mg-for-acute-gastroenteritis-idUSFWN1R90JI",
    "ord_in_thread": 0,
    "title": "BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 13 PM / Updated 18 minutes ago BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis Reuters Staff 1 Min Read March 27 (Reuters) - Redhill Biopharma Ltd: * REDHILL BIOPHARMA ANNOUNCES TWO ORAL PRESENTATIONS ON BEKINDA® 24 MG FOR ACUTE GASTROENTERITIS AT THE SAEM 2018 ANNUAL MEETING * REDHILL BIOPHARMA -RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III GUARD STUDY WITH BEKINDA 24 MG SUCCESSFULLY MET ITS PRIMARY ENDPOINT * BEKINDA 24 MG WAS ALSO FOUND TO BE SAFE AND WELL TOLERATED IN TREATMENT OF ACUTE GASTROENTERITIS AND GASTRITIS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-03-27T15:09:00.000+03:00",
    "crawled": "2018-03-27T15:35:48.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "biopharma",
        "announces",
        "two",
        "oral",
        "presentation",
        "mg",
        "acute",
        "gastroenteritis",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "redhill",
        "biopharma",
        "ltd",
        "redhill",
        "biopharma",
        "announces",
        "two",
        "oral",
        "presentation",
        "mg",
        "acute",
        "gastroenteritis",
        "saem",
        "annual",
        "meeting",
        "redhill",
        "biopharma",
        "phase",
        "iii",
        "guard",
        "study",
        "bekinda",
        "mg",
        "successfully",
        "met",
        "primary",
        "endpoint",
        "bekinda",
        "mg",
        "also",
        "found",
        "safe",
        "well",
        "tolerated",
        "treatment",
        "acute",
        "gastroenteritis",
        "gastritis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}